Newswire (Published: Tuesday, January 21, 2020, Received: Tuesday, January 21, 2020, 6:19:38 PM CST)

Word Count: 494

2020 JAN 21 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Daily -- Research findings on Oncology - Prostate Cancer are discussed in a new report. According to news reporting out of Hannover, Germany, by NewsRx editors, research stated, “Prostate-specific membrane antigen (PSMA)-targeted PET imaging for prostate cancer with Ga-labeled compounds has rapidly become adopted as part of routine clinical care in many parts of the world. However, recent years have witnessed the start of a shift from Ga-to F-labeled PSMA-targeted compounds.”

Our news journalists obtained a quote from the research from Hannover Medical School, “The latter imaging agents have several key advantages, which may lay the groundwork for an even more widespread adoption into the clinic. First, facilitated delivery from distant suppliers expands the availability of PET radiopharmaceuticals in smaller hospitals operating a PET center but lacking the patient volume to justify an onsite Ge/Ga generator. Thus, such an approach meets the increasing demand for PSMA-targeted PET imaging in areas with lower population density and may even lead to cost-savings compared to in-house production. Moreover, F-labeled radiotracers have a higher positron yield and lower positron energy, which in turn decreases image noise, improves contrast resolution, and maximizes the likelihood of detecting subtle lesions. In addition, the longer half-life of 110 min allows for improved delayed imaging protocols and flexibility in study design, which may further increase diagnostic accuracy. Moreover, such compounds can be distributed to sites which are not allowed to produce radiotracers on-site due to regulatory issues or to centers without access to a cyclotron. In light of these advantageous characteristics, F-labeled PSMA-targeted PET radiotracers may play an important role in both optimizing this transformative imaging modality and making it widely available. We have aimed to provide a concise overview of emerging F-labeled PSMA-targeted radiotracers undergoing active clinical development.”

According to the news editors, the research concluded: “Given the wide array of available radiotracers, comparative studies are needed to firmly establish the role of the available F-labeled compounds in the field of molecular PCa imaging, preferably in different clinical scenarios.”

For more information on this research see: 18F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging. Theranostics, 2020;10(1):1-16.

Our news journalists report that additional information may be obtained by contacting R.A. Werner, Dept. of Nuclear Medicine, Hannover School of Medicine, Hannover, Germany. Additional authors for this research include T. Derlin, C. Lapa, S. Sheikbahaei, T. Higuchi, F.L. Giesel, S. Behr, A. Drzezga, H. Kimura, A.K. Buck, F.M. Bengel, M.G. Pomper, M.A. Gorin and S.P Rowe.

The direct object identifier (DOI) for that additional information is: This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)


      Imaging Agents


Western Europe


Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Treatments and Therapies
            Medicinal Drugs